Susan Wolfsthal. NMS medicine: 7th Edition. — Защищенный просмотр

Документти басып чыгарууга тыюу салынат

Бул документ автордук укук менен корголгон жана электрондук китепканада окуу үчүн гана арналган. Укук ээсинин уруксатысыз көчүрүүгө, сактоого жана басып чыгарууга жол берилбейт.

ЭЛЕКТРОННАЯ БИБЛИОТЕКА КНУ

Печать документа запрещена

Этот документ защищён авторским правом и предназначен исключительно для просмотра в электронной библиотеке. Копирование, сохранение и печать без разрешения правообладателя не допускаются.

Susan Wolfsthal. NMS medicine: 7th Edition.

АвторSusan Wolfsthal

Год издания2012

Аннотация⌄

Care has been taken to confi rm the accuracy of the information present and to describe generally accepted practices.
However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner; the clinical treatments described and recommended may not be considered absolute and universal recommendations.
The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with the current recommendations and practice at the time of publication.
However, in view of ongoing research, changes in government regulations, and the constant fl ow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.
Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in his or her clinical practice.